Navigation Links
Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology
Date:10/4/2010

er (median 14.5 months versus 12.5 months; hazard ratio 0.85; 95 percent CI: 0.70-1.04), the improvement in overall survival (co-primary endpoint) in the Vectibix arm did not achieve statistical significance (p=0.12) in the same patient population.
  • The addition of Vectibix to chemotherapy in the '181' trial resulted in greater than a three-fold improvement (35 percent versus 10 percent) in response rate in the wild-type KRAS patient population, as measured by a blinded central review.
  • Tumor KRAS status was ascertained in 91 percent of the 1,186 patients enrolled in the '181' trial, the highest number ever prospectively reported for a second-line trial.
  • In this study, the addition of Vectibix had no positive or negative effect on PFS or OS in patients with tumors harboring activating KRAS mutations.

  • "The response rate seen in the '181' trial is among the highest ever reported in the second-line metastatic colorectal cancer setting," said Emily Chan, M.D., Ph.D., Assistant Professor of Medicine, Vanderbilt-Ingram Cancer Center and '181' study investigator and author. "Additionally, the tissue acquisition from both the '181' and '203' studies has yielded a large repository of informative data regarding the KRAS biomarker, and holds the potential of providing even more information in the future."

    In general, adverse events rates were comparable across arms in both studies, with the exception of known toxicities associated with anti-EGFR therapy, such as rash, diarrhea, and hypomagnesemia. Vectibix-related grade 3/4 infusion reactions were reported in less than one percent of patients.

    Originally designed to compare the treatment effect in the overall mCRC patient population, both studies were amended to analyze outcomes with respect to the presence or absence of activating mutations in KRAS in the tumor itself. These are the first Phase 3 studies to prospectively analyze the effect of
    '/>"/>

    SOURCE Amgen
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11

    Related biology technology :

    1. NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients
    2. Positive SPA Reply From the FDA for TopoTargets Pivotal Trial With Belinostat in PTCL
    3. Fifth DuraHeart(TM) U.S. Implant Marks Important Milestone in U.S. Pivotal Trial
    4. Oncolytics Biotech Inc. Announces Decision to Pursue Phase II/III Pivotal Clinical Trial
    5. Genmab A/S: Ofatumumab Pivotal CLL Data to be Presented at ASH
    6. Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Reaches Halfway Point
    7. BioSyntech to conclude enrolment for pivotal BST-CarGel(R) trial in February 2009
    8. BioSyntech Achieves Enrolment Goal for Pivotal Trial of BST-CarGel(R), its Cartilage Repair Device
    9. ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results
    10. PROVENGE Significantly Prolongs Survival in Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study
    11. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/20/2014)... , Oct. 20, 2014 PureTech ... company tackling big healthcare problems, announced today the ... round, with participation from Invesco Perpetual, a $120 ... used to drive PureTech,s existing pipeline forward and ... "PureTech has the scientific creativity to really go ...
    (Date:10/19/2014)... Latin American hardware encryption display market report defines and ... forecast of revenue. This market was valued at $165.0 ... million by 2018, at a CAGR of 70.3% from ... the Latin American hardware encryption market report to get ... provides a glimpse of the segmentation of the market, ...
    (Date:10/19/2014)... The Asian Automatic patient billing report defines and ... of revenue. The Automatic patient billing market in Asia ... 2018, at a developing CAGR of 7.2% from 2013 ... Asian Automatic patient billing market, to get an idea ... glimpse of the segmentation of this market in the ...
    (Date:10/19/2014)... The report "Unmanned Ground Vehicle ... Technology, Payload, Type & by Geography - Forecasts ... unmanned ground vehicle market into various sub segments ... sizes. The report also identifies the factors driving ... along with the adoption trends. , The unmanned ...
    Breaking Biology Technology:PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 2The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 3The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 2The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 3Unmanned Ground Vehicle (UGV) Market Estimated to Reach $8.26 Billion by 2020 - New Research Report by MarketsandMarkets 2Unmanned Ground Vehicle (UGV) Market Estimated to Reach $8.26 Billion by 2020 - New Research Report by MarketsandMarkets 3Unmanned Ground Vehicle (UGV) Market Estimated to Reach $8.26 Billion by 2020 - New Research Report by MarketsandMarkets 4Unmanned Ground Vehicle (UGV) Market Estimated to Reach $8.26 Billion by 2020 - New Research Report by MarketsandMarkets 5
    ... 22, 2011 With the intent to create a ... Akron, the Austen BioInnovation Institute in Akron (ABIA) has ... "Healthier by Design: Creating Accountable Care Communities" held today. ... and wellness thought-leaders, the strategic discussion is the first ...
    ... BASEL, Switzerland, June 22, 2011 The Roche manuscript: ... Production of Bispecific IgG Antibodies" has been published in ... of the USA (PNAS). Corresponding authors are ... at Penzberg, and Christian Klein, Head of Oncology Programs, ...
    ... ,   Crescendo ... Roe as Chief Business Officer. Matthew joins,Crescendo from ... & Licensing. During a 23-year career ... acquisition, divestment, and sales,and marketing, and saw the ...
    Cached Biology Technology:Austen BioInnovation Institute in Akron Begins Work on Roadmap for First U.S. Accountable Care Community 2Austen BioInnovation Institute in Akron Begins Work on Roadmap for First U.S. Accountable Care Community 3Proceedings of the National Academy of Sciences (PNAS) Publishes Roche Manuscript on Production of Bispecific IgG Antibodies 2Crescendo Biologics Appoints Matthew Roe as Chief Business Officer 2
    (Date:10/14/2014)... N.Y. – Scientists have sequenced the house fly genome ... one might expect from an insect that thrives in ... published Oct. 14 in the journal Genome Biology ... biology and of how flies quickly adapt to resist ... Adult house flies (Musca domestica) carry and transmit more ...
    (Date:10/14/2014)... team has discovered a new kind of stem cell that ... lines liver blood vessels, according to a study published today ... of such a cell type contradicts current theory on how ... hold clues to origins of, and future treatment for, liver ... cell into a complex being made up of more than ...
    (Date:10/14/2014)... October 14, 2014 – Scientists from The Scripps Research ... National Institutes of Health (NIH) to lead an investigation ... fever disease in Africa. The study aims to understand ... patients die, while others survive the inflection. , ... basic mechanism of how Lassa fever virus causes disease ...
    Breaking Biology News(10 mins):House fly genome reveals expanded immune system 2Stem cell discovery challenges dogma on how fetus develops; holds insights for liver cancer and reg 2Stem cell discovery challenges dogma on how fetus develops; holds insights for liver cancer and reg 3Scripps Research Institute team receives $6.6 million to investigate deadly Lassa virus 2
    ... will leave the lab this summer to apply ... skills at workshops held around the country by ... in science majors grows, college-level science teaching must ... inquiry-based learning, according to MSU plant biology professor ...
    ... has patented an improved microscopy method for measuring the ... create new pharmaceuticals that are a better match for ... Aberration Correction (DAC) microscopy, measures distances at the molecular ... microscopy. A special feature of the new method, ...
    ... Feb. 6, 2009 Complete Genomics, Inc. released proof-of-concept ... the first time yesterday evening. The analysis results were ... and CEO, during his presentation at the annual Advances ... Marco Island Marriott Beach Resort, Marco Island, Fla. ...
    Cached Biology News:NSF-funded workshops help young researchers teach science 2Measuring molecules to improve drug design 2Complete Genomics releases proof-of-concept data for its sequencing technology for the first time 2Complete Genomics releases proof-of-concept data for its sequencing technology for the first time 3
    The SVT3-2 diverter valve is a 3-port, 2-position valve for use with the BioLogic DuoFlow system....
    ... for 2-D separations. The cell has a six-gel ... xi multi-cell can be customized for several parameters: ... cooling system. The PROTEAN II xi multi-cell can ... multi-cell for a wider format that accommodates 17 ...
    ... 16 cm, is used for vertical slab gel ... gels. The cell is supplied without spacers and ... with gaskets, lower buffer chamber, lid with cables, ... upper buffer dam, casting stand with gaskets, leveling ...
    CleanCut agarose is used to prepare genomic DNA plugs for use in pulsed field gel electrophoresis (PFGE) applications. Supplied as a 12 ml solution of 2% agarose....
    Biology Products: